November 12, 2019 / 12:04 PM / a month ago

Solid Biosciences gene therapy trial put on hold by FDA

Nov 12 (Reuters) - Solid Biosciences Inc said on Tuesday the U.S. Food and Drug Administration has put on hold a trial testing its gene therapy for a muscle-wasting disorder.

Last month one of the six patients with Duchenne muscular dystrophy dosed with the company's drug, SGT-001, experienced a serious side effect that was deemed related to the treatment, the company said. (Reporting by Tamara Mathias in Bengaluru; Editing by Sriraj Kalluvila)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below